ArticleArchives of Razi Institute2024
Protective and Antioxidant Effects of Quercetin Loaded Black Cumin (
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Combination of Nigella sativa Oil-Based Nanoemulsion and Quercetin Alleviates Oxidative Stress From Exogenous Testosterone Through Antioxidant and Anti-Inflammatory Mechanisms in Rats.Veterinary medicine and science · 2026Article
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin (Qu) is a type of plant flavonoid that has been demonstrated to possess anti-proliferative properties, making it a potentially beneficial agent in the treatment of prostate hyperplasia. Additionally, Nigella sativa seed oil (NSO) has demonstrated efficacy in alleviating symptoms associated with benign prostatic hyperplasia (BPH). The objective of this study is to evaluate the impact of quercetin (Qu) in combination with a nanoemulsion derived from Nigella sativa seed oil (Qu-NSO) on a rat model of benign prostatic hyperplasia (BPH). The study employed a rat model of BPH, whereby testosterone enanthate (5 mg/kg) was administered subcutaneously to induce the condition. The rats were then treated with various interventions, including Qu (25 mg/kg and 50 mg/kg), NSO, and Qu-NSO (25 mg/kg and 50 mg/kg), with a total volume of 0.5 ml administered orally. This allowed for an assessment of the effects of Qu-NSO. The self-nanoemulsified drug delivery system was prepared using NSO, coconut oil, Tween 80, and polyethylene glycol 400 (PEG). The globule size and zeta potential of the formed vesicles were determined. Investigations were conducted on the rat model to examine the effects of the treatments on dihydrotestosterone (DHT), prostate-specific antigen (PSA), prostatic weight and index, oxidant and antioxidant markers, and histopathology. The mean globule size for Qu-NSO was 171.9±10.9 nm, with a zeta potential value of +17.3 mV. The Qu-NSO treatment resulted in a 40% reduction in prostate weight and an 86.71% reduction in prostate index compared to the testosterone-treated group. The Qu-NSO treatment resulted in a significant reduction in serum levels of oxidative contents (MDA) (p<0.0001), while antioxidative substances (SOD and GPx activity) exhibited a significant increase (p<0.0001). The Qu-NSO group exhibited superior outcomes in terms of decreasing prostatic weight and enhancing antioxidative properties, as evidenced by elevated antioxidant enzyme activity. This study demonstrated that the Qu and NSO in a Qu NSO formula augmented the Qu efficacy in managing BPH. Quercetin (Qu) is a type of plant flavonoid that is beneficial in fighting prostate hyperplasia cells. Meanwhile,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.